CTOs on the Move

SI Group

www.siigroup.com

 
SI Group is a leading global developer and manufacturer of chemical intermediates, specialty resins and solutions that are critical to the quality and performance of countless industrial and consumer goods. We`re a global leader with a local presence in 10 countries, more than 2,700 employees, and customers in more than 90 countries. Our people, facilities and integrated supply chain deliver products and solutions where our customers need them, when they need them. Our focus is on ten key market segments—rubber resins, antioxidants, fuels and lubricants, plastic additives, industrial resins, health and wellness, adhesive resins, surfactants, engineering plastics and pharma and specialty. We provide ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.siigroup.com
  • 2750 Balltown Road
    Schenectady, NY USA 12301
  • Phone: 518.347.4200

Executives

Name Title Contact Details

Similar Companies

EnteraTech

EnteraTech is a Hilliard, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dendritic NanoTechnologies

Dendritic NanoTechnologies is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precept Life Sciences

Precept Life Sciences is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hawaii Chitopure

Hawaii Chitopure is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ultragenyx Pharmaceutical

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx`s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.